Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Atopaxar.

T Wurster, A E May

    Hamostaseologie
    |March 29, 2018
    PubMed
    Summary
    This summary is machine-generated.

    Atopaxar, a novel PAR-1 antagonist, shows promise for preventing recurrent ischemic events in high-risk patients. While generally well-tolerated, further Phase III trials are needed to confirm its efficacy and safety profile.

    Related Concept Videos

    You might also read

    Related Articles

    Articles linked to this work by shared authors, journal, and citation graph.

    Sort by
    Same author

    Effects of hypoxia and low temperature on female physiology and reproduction of <i>Drosophila melanogaster</i>.

    bioRxiv : the preprint server for biology·2026
    Same author

    Evidence for the Collective Nature of Radial Flow in Pb+Pb Collisions with the ATLAS Detector.

    Physical review letters·2026
    Same author

    Evidence for the Dimuon Decay of the Higgs Boson in pp Collisions with the ATLAS Detector.

    Physical review letters·2025
    Same author

    Evidence for Longitudinally Polarized W Bosons in the Electroweak Production of Same-Sign W Boson Pairs in Association with Two Jets in pp Collisions at sqrt[s]=13  TeV with the ATLAS Detector.

    Physical review letters·2025
    Same author

    Observation of tt[over ¯] Production in Pb+Pb Collisions at sqrt[s_{NN}]=5.02  TeV with the ATLAS Detector.

    Physical review letters·2025
    Same author

    Search for Dark Matter Produced in Association with a Dark Higgs Boson in the bb[over ¯] Final State Using pp Collisions at sqrt[s]=13  TeV with the ATLAS Detector.

    Physical review letters·2025
    Same journal

    Diagnosis and Management of Immune Platelet Transfusion Refractoriness.

    Hamostaseologie·2026
    Same journal

    Too Common to Ignore: Decoding the Complexity of the FGG p.Ala108Gly Variant in Fibrinogen Disorders.

    Hamostaseologie·2026
    Same journal

    Hamostaseologie·2026
    Same journal

    Hamostaseologie·2026
    Same journal

    Hamostaseologie·2026
    Same journal

    Hamostaseologie·2026
    See all related articles

    Area of Science:

    • Cardiovascular Pharmacology
    • Thrombosis Research
    • Drug Development

    Background:

    • Atopaxar (E 5555) is a novel, reversible protease-activated receptor-1 (PAR-1) thrombin receptor antagonist.
    • Investigated in Phase II trials for safety and tolerability in patients with acute coronary syndromes or stable coronary artery disease.

    Purpose of the Study:

    • To evaluate the safety and tolerability of Atopaxar when added to standard antiplatelet therapy.
    • To explore potential efficacy signals in patients at high risk for recurrent ischemic events.

    Main Methods:

    • Phase II clinical trials involving patients with coronary artery disease.
    • Assessment of safety endpoints including liver enzymes, QTcF interval, and bleeding complications.
    • Exploratory analysis of potential efficacy in preventing ischemic events.

    Related Experiment Videos

    Main Results:

    • Atopaxar was generally well-tolerated.
    • Observed side effects included a rise in liver enzymes and QTcF interval prolongation.
    • Minor bleeding complications were noted, but the risk of major bleeding was not significantly increased.
    • Preliminary data suggest potential benefits in reducing recurrent ischemic events.

    Conclusions:

    • Atopaxar demonstrates an acceptable safety profile in Phase II trials.
    • Further Phase III studies are necessary to definitively establish the efficacy and safety of Atopaxar.
    • Atopaxar may offer a therapeutic option for high-risk cardiovascular patients on antiplatelet therapy.